Loading clinical trials...
Loading clinical trials...
A Phase 1b, Exploratory Study to Assess the Safety, Tolerability, Colonic Tissue Exposure, and Anti-Inflammatory Effects of Two Different Doses of SRT2104 in Subjects With Mild to Moderate Ulcerative Colitis
Conditions
Interventions
SRT2104
Locations
13
United States
GSK Investigational Site
Anaheim, California, United States
GSK Investigational Site
Bristol, Connecticut, United States
GSK Investigational Site
Owensboro, Kentucky, United States
GSK Investigational Site
Chevy Chase, Maryland, United States
GSK Investigational Site
Towson, Maryland, United States
GSK Investigational Site
Chesterfield, Michigan, United States
Start Date
February 13, 2012
Primary Completion Date
March 18, 2013
Completion Date
March 18, 2013
Last Updated
June 1, 2017
NCT05076175
NCT06651281
NCT04121806
NCT06065228
NCT06892990
NCT03596645
Lead Sponsor
Sirtris, a GSK Company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions